|
Launching FieldScreen™, a novel in silico technology from Cresset BioMolecular Discovery Limited
Brief
Cresset BioMolecular Discovery, a drug discovery technology company from Hertfordshire in the UK, launched its new FieldScreen™ technology and College Hill Life Sciences was hired to ensure that this received maximum publicity in the trade press.
Objectives
 |
The primary objective was to get the name of Cresset and the FieldScreen™ technology known in the target audiences of biotechnology and pharmaceutical R&D |
| |
The secondary objective was to ensure that coverage resulting from the launch was clear about the unique but complex basis of the technology
|
Methods
| |
In preparation for the announcement a press release and distribution list were prepared |
| |
The announcement was timed to coincide with the Genesis conference and interviews were lined up in advance with journalists attending the event |
| |
Northbank liaised with key journalists in the relevant trade press to ensure they were aware of the story and its importance to the biotechnology industry |
| |
Telephone interviews were set up on the day with specially interested journalists
|
Results
| |
Interviews were arranged at Genesis with Genetic Engineering News, Drug Discovery World and Drug News (R&D Focus)
|
| |
Telephone interviews were co-ordinated with Scrip and Dow Jones Venturewire |
| |
The story appeared in key trade media including substantial profiles in Scrip, Dow Jones Venturewire, Drug News (R&D Focus) and Genetic Engineering News |
| |
Additional coverage was published in BioCentury, HT Screening, Drug Researcher, BioXCompare, BioPortfolio and Bioscreening |
| |
Online coverage was achieved |
9 December 2004
To discuss our capability in this area please contact:
Sue Charles, Managing Partner
+44 (0)20 7457 2020
sue.charles[at]collegehill.com
|
Quick links
